Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.
暂无分享,去创建一个
C Sennett | S M Grundy | S. Grundy | J. Cleeman | R. Pasternak | T. H. Lee | R C Pasternak | T H Lee | J I Cleeman | C. Gillett | C. Sennett | C Gillett | J Seidman | J. Seidman | T. H. Lee | T. Lee
[1] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[2] V. Fuster,et al. Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.
[3] J. Neaton,et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.
[4] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[5] S. Grundy,et al. Statin trials and goals of cholesterol-lowering therapy. , 1998, Circulation.
[6] J P Matts,et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.
[7] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[8] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.
[9] B. Davis,et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.
[10] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[11] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[12] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[13] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[14] N J Wald,et al. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.
[15] G. Thorgeirsson,et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.
[16] R L Brown,et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. , 1998, Archives of internal medicine.